Steminent Biotherapeutics Inc. (TPEX:7729)
Taiwan · Delayed Price · Currency is TWD 77.60
+0.80 (1.04%)
Sep 8, 2026, 12:48 PM CST
Steminent Biotherapeutics Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| - | - | - | 0.94 | 0.64 | 2.12 | |
Revenue Growth | - | - | - | 47.96% | -70.01% | -95.88% |
Cost of Revenue | 3.45 | 0.79 | 6.09 | 1.98 | 9.57 | 3.87 |
Gross Profit | -3.45 | -0.79 | -6.09 | -1.04 | -8.93 | -1.75 |
Selling, General & Admin | 77.59 | 57.6 | 45.83 | 62.7 | 33.87 | 25.76 |
Research & Development | 127.51 | 115.28 | 110.38 | 67.73 | 55.41 | 48.09 |
Operating Expenses | 205.09 | 172.87 | 156.21 | 130.42 | 89.28 | 73.85 |
Operating Income | -208.54 | -173.66 | -162.3 | -131.46 | -98.21 | -75.6 |
Interest Expense | -2.08 | -2.15 | -1.92 | -1.78 | -0.9 | -1.33 |
Interest & Investment Income | 4.58 | 2.51 | 4.13 | 2.96 | 0.85 | 0.07 |
Currency Exchange Gain (Loss) | -0.87 | -0.87 | 1.34 | -0.02 | 2.8 | -0.8 |
Other Non Operating Income (Expenses) | 2.34 | 0.02 | 0.14 | 1.08 | 9.99 | -46.1 |
EBT Excluding Unusual Items | -204.58 | -174.15 | -158.6 | -129.23 | -85.47 | -123.75 |
Gain (Loss) on Sale of Investments | - | - | - | - | - | -0.46 |
Gain (Loss) on Sale of Assets | - | - | - | - | - | 0 |
Pretax Income | -204.58 | -174.15 | -158.6 | -129.23 | -85.47 | -124.2 |
Income Tax Expense | -0.11 | -0.11 | 0.15 | - | - | - |
Net Income | -204.46 | -174.04 | -158.75 | -129.23 | -85.47 | -124.2 |
Net Income to Common | -204.46 | -174.04 | -158.75 | -129.23 | -85.47 | -124.2 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 68 | 59 | 56 | 48 | 44 | 35 |
Shares Outstanding (Diluted) | 68 | 59 | 56 | 48 | 44 | 35 |
Shares Change | 20.73% | 5.49% | 15.42% | 8.84% | 26.27% | 17.57% |
EPS (Basic) | -3.02 | -2.95 | -2.84 | -2.67 | -1.92 | -3.52 |
EPS (Diluted) | -3.03 | -2.95 | -2.84 | -2.67 | -1.92 | -3.52 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -178.83 | -140.07 | -226.57 | -142.27 | -71.52 | -55.71 |
Free Cash Flow Per Share | -2.64 | -2.38 | -4.05 | -2.94 | -1.61 | -1.58 |
Gross Margin | - | - | - | -110.10% | - | -82.32% |
Operating Margin | - | - | - | -13970.14% | -15442.14% | -3564.12% |
Profit Margin | - | - | - | -13733.16% | -13439.31% | -5855.78% |
Free Cash Flow Margin | - | - | - | -15119.02% | -11245.28% | -2626.69% |
EBITDA | -189.03 | -155.03 | -158.14 | -129.51 | -96.59 | -71.91 |
D&A For EBITDA | 19.51 | 18.63 | 4.15 | 1.95 | 1.62 | 3.69 |
EBIT | -208.54 | -173.66 | -162.3 | -131.46 | -98.21 | -75.6 |